ZURAZura Bio LimitedHealthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $4.61 · now $4.61 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, ZURA has typically landed between $2.98 and $7.34 — a range of −35.4% to +59.2% from the issuance price $4.61.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

854 overlapping 1 month windows · 2023-03-212026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($4.61) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where ZURA has typically landed a month from the 2026-09-16 close of $4.61 — the range is history, not a prediction.

$2.98worst · -35.4%$7.34best · +59.2%
  • now $4.61 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $4.6 (-0.1%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $3.88$5.33
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $2.98$7.34
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 854 windows spanning 2023-03-21 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2023-03-23−75.5%−75.5%+0.0%
2023-03-24−73.7%−73.7%+0.0%
2023-04-03−64.8%−64.8%+0.0%
3 best
2023-05-18+144.3%−1.3%+144.3%
2023-05-22+125.7%+0.0%+141.5%
2023-05-19+124.8%+0.0%+147.6%

854 overlapping windows · 2023-03-212026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~4 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
33%
−18.5%
n=3
Feb
67%
+6.0%
n=3
Mar
0%
−15.1%
n=3
Apr
50%
+4.1%
n=4
May
25%
−11.0%
n=4
Jun
75%
+13.3%
n=4
Jul
50%
+5.5%
n=4
Aug
75%
+13.1%
n=4
Sep
25%
+22.4%
n=4
Oct
33%
−10.6%
n=3
Nov
33%
−9.2%
n=3
Dec
33%
+4.9%
n=3

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$7$12026-02-26: 1 insider purchase, $12.5M — AI Biotechnology LLC2026-02: 1 open-market purchase, $12.5M↑ buys↓ salestenPercentOwner AI Biotechnology LLC — Purchase on 2026-02-26, filed 4 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-02-26AI Biotechnology LLCtenPercentOwnerPurchase2,000,000 @ $6.25$12.5M+43.9% of holding−4.6%−26.0%6,552,725Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

41 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-17Jarrett JenniferdirectorAward / grant51,00051,000Form 4
2026-06-17Munshi AmitdirectorAward / grant51,00051,000Form 4
2026-06-17Becker Daniel J.directorAward / grant51,00051,000Form 4
2026-06-17Nirula AjaydirectorAward / grant51,00051,000Form 4
2026-06-17Schoch Steven JdirectorAward / grant51,00051,000Form 4
2026-06-17Thiara ParvinderdirectorAward / grant51,00051,000Form 4
2026-06-17Eisner MarkdirectorAward / grant51,00051,000Form 4
2026-04-01Davis KimofficerAward / grant425,700425,700Form 4
2026-04-01Kulkarni Sandeep ChidambardirectorAward / grant894,000894,000Form 4
2026-04-01Whale GaryofficerAward / grant263,000263,000Form 4
2026-04-01Nistala KiranofficerAward / grant340,900340,900Form 4
2026-04-01Hyllengren Eric JofficerAward / grant340,900340,900Form 4
2026-02-21Nirula AjaydirectorAward / grant37,81237,812Form 4
2026-02-21Eisner MarkdirectorAward / grant37,81237,812Form 4
2026-01-23Thiara ParvinderdirectorAward / grant38,82338,823Form 4
2026-01-21Kulkarni Sandeep ChidambardirectorAward / grant2,934,1072,934,107Form 4
2025-07-15Hyllengren Eric JofficerAward / grant672,000672,000Form 4
2025-05-29Becker Daniel J.directorAward / grant51,00051,000Form 4
2025-05-21Jarrett JenniferdirectorAward / grant51,00051,000Form 4
2025-05-21Graham Neil Murray HamiltondirectorAward / grant51,00051,000Form 4
2025-05-21Munshi AmitdirectorAward / grant51,00051,000Form 4
2025-05-21Sidhu SomeitdirectorAward / grant51,00051,000Form 4
2025-05-21Schoch Steven JdirectorAward / grant51,00051,000Form 4
2025-05-21Kulkarni Sandeep ChidambardirectorAward / grant51,00051,000Form 4
2025-05-21Ploos van Amstel ArnoutdirectorAward / grant51,00051,000Form 4
2025-05-08Badial Verender S.officerAward / grant303,100303,100Form 4
2025-02-27Whale GaryofficerAward / grant302,000302,000Form 4
2025-02-27Nistala KiranofficerAward / grant341,700341,700Form 4
2025-02-27Lisicki RobertdirectorAward / grant1,153,0001,153,000Form 4
2025-02-27Davis KimofficerAward / grant488,800488,800Form 4
2024-12-09Ploos van Amstel ArnoutdirectorAward / grant117,000117,000Form 4
2024-12-09Schoch Steven JdirectorAward / grant117,000117,000Form 4
2024-12-09Sidhu SomeitdirectorAward / grant117,000117,000Form 4
2024-12-09Thiara ParvinderdirectorAward / grant117,000117,000Form 4
2024-12-09Lisicki RobertdirectorAward / grant117,000117,000Form 4
2024-12-09Graham Neil Murray HamiltondirectorAward / grant117,000117,000Form 4
2024-12-09Jarrett JenniferdirectorAward / grant117,000117,000Form 4
2024-12-09Kulkarni Sandeep ChidambardirectorAward / grant117,000117,000Form 4
2024-12-09Munshi AmitdirectorAward / grant117,000117,000Form 4
2024-09-16Davis KimofficerAward / grant1,0001,500Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.